Pharming Group N.V Asset Turnover Growth & History (PHAR)
Pharming Group N.V's asset turnover was 0.84 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.84 | 0.15 | +21.34% |
| 2024 | 2024-12-31 | 0.69 | 0.14 | +24.77% |
| 2023 | 2023-12-31 | 0.55 | 0.05 | +10.51% |
| 2022 | 2022-12-31 | 0.50 | 0.01 | +2.47% |
| 2021 | 2021-12-31 | 0.49 | −0.14 | −22.52% |
| 2020 | 2020-12-31 | 0.63 | — | — |
Pharming Group N.V quarterly asset turnover
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.80 | — | — |
| Q1 2026 | 2026-03-31 | 0.83 | — | — |
Pharming Group N.V asset turnover trends
Over the last five fiscal years, Pharming Group N.V's asset turnover increased from 0.63 to 0.84, a change of 0.21. The latest reported quarter, Q2 2026, shows 0.80.
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...